The Immunology of Bronchial Carcinoma

  • Bryan H. R. Stack


In the nineteeth century, the first successful attempts to immunise patients against infectious diseases were made. It was probably this concept of active immunisation that led investigators to consider whether it would be possible to immunise patients against tumours that were already established (Currie 1972). The early investigations involved two types of immunological stimulant. The first consisted of cells or extracts taken from the patient’s own tumour (autologous) or from one or more tumours extracted from other patients (allogeneic) (Von Leyden and Blumenthal 1902). The second consisted of non-specific bacterial antigens; for example, Loeffler (1901) described injection of staphylococci and later tubercle bacilli in patients with advanced cancer.


Lung Cancer Patient Malignant Pleural Effusion Bronchogenic Carcinoma Mixed Lymphocyte Culture Bronchial Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abbey Smith R (1970) Long term clinical follow-up after operation for carcinoma. Thorax 25: 62–76PubMedCrossRefGoogle Scholar
  2. Abrams PG, Cuttita FC, Kimball E, Minna JD (1982) A monoclonal antibody specific for non-small cell bronchogenic carcinoma. In: Abstracts of the 3rd World Conference on Lung Cancer, IASLC, Tokyo, p 49Google Scholar
  3. Amery WKPC (1980) Adjuvant levamisole in the treatment of patients with resectable lung cancer. Ann Clin Res 12 [Suppl 271: 1–83Google Scholar
  4. Anthony HM (1982) Blood basophils in lung cancer. Br J Cancer 45: 209–216PubMedCrossRefGoogle Scholar
  5. Anthony HM, Kirk JA, Madsen KE, Mason MK, Templeman GH (1975) E and EAC rosetting lymphocytes in patients with carcinoma of bronchus. Clin Exp Immunol 20: 41–54Google Scholar
  6. Anthony HM, Mearns AJ, Mason MK et al. (1979). Levamisole and surgery in bronchial carcinoma patients: increase in deaths from cardiorespiratory failure. Thorax 34: 4–12PubMedCrossRefGoogle Scholar
  7. Barnes EW, Farmer A, Penhale WJ, Irvine WJ, Roscoe P, Horne NW (1975) Phytohemagglutinininduced lymphocyte transformation in newly presenting patients with primary carcinoma of the lung. Cancer 36: 187–193PubMedCrossRefGoogle Scholar
  8. Bell CE, Seetharam S (1976) A plasma membrane antigen highly associated with oat-cell carcinoma of the lung and undetectable in normal adult tissue. Int J Cancer 18: 605–611PubMedCrossRefGoogle Scholar
  9. Blades B, McCorkle R (1954) A case of spontaneous regression of an untreated bronchogenic carcinoma. J Thorac Surg 27: 415–419PubMedGoogle Scholar
  10. Broder LE (1980) Marker substances in bronchogenic carcinoma — emphasis on carcinoembryonic antigen (CEA) and human chorionic gonadotropin (HCG). In: Hansen HH, Dombernowsky P (eds) Abstracts of Second World Conference on Lung CancerGoogle Scholar
  11. Brzyski H, Konchanin L, Baustin A, Ruckdeschel JC (1979) Abnormal mitogen-induced lymphocyte proliferation in patients with lung cancer: possible role of the surface modulating assembly. Proc Am Assoc Cancer Res 20: 148Google Scholar
  12. Currie GA (1972) Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. Br J Cancer 26: 141–153PubMedCrossRefGoogle Scholar
  13. Dent RG, Cole P (1981) In vitro monocyte maturation as a prediction of survival in squamous cell carcinoma of the lung. Thorax 36: 446–451PubMedCrossRefGoogle Scholar
  14. Djurovic V, Decroix G (1977) Postoperative non-specific immunotherapy in primary bronchogenic carcinoma. Rec Res Cancer Res 62: 156–163Google Scholar
  15. Edwards FR, Whitwell F (1978) Use of BCG as an immunostimulant in the surgical treatment of carcinoma of lung: a five year follow-up report. Thorax 33: 250–252PubMedCrossRefGoogle Scholar
  16. Everson TC, Cole WH (1956) Spontaneous regression of cancer: preliminary report. Ann Surg 144: 366–383PubMedCrossRefGoogle Scholar
  17. Felletti R, Ravazzoni C (1983) Intrapleural C. parvum for malignant pleural effusions. Thorax 38: 22–24PubMedCrossRefGoogle Scholar
  18. Ford CHJ, Newman CE, Lakin J (1977) Role of carcinoembryonic antigen in bronchial carcinoma. Thorax 32: 582–588PubMedCrossRefGoogle Scholar
  19. Fox RM, Woods RL, Tattersall MHN, Basten A (1980) A randomised study of adjuvant immunotherapy with levamisole and Corynebacterium parvum in operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 6: 1043–1045PubMedCrossRefGoogle Scholar
  20. Frost MT, Rogers GT, Bagshawe KD (1975) Extraction and preliminary characterisation of a human bronchogenic carcinoma antigen. Br J Cancer 31: 379–386PubMedCrossRefGoogle Scholar
  21. Geddes DM (1979) The natural history of lung cancer: a review based on rates of tumour growth. Br J Dis Chest 73: 1–17PubMedCrossRefGoogle Scholar
  22. Gropp C, Havemann K, Scheuer A (1980) The use of carcinoembryonic antigen and peptide hormones to stage and monitor patients with lung cancer. Int J Radiat Oncol Biol Phys 6: 1047–1053PubMedCrossRefGoogle Scholar
  23. Guiliano AE, Rangel D, Golub SH, Holmes EC, Morton DL (1979) Serum-mediated immunosuppression in lung cancer. Cancer 43: 917–924CrossRefGoogle Scholar
  24. Guy K, Di Mario U, Irvine WJ, Hunter AM, Hadley A, Horne NW (1981) Circulating immune complexes and auto-antibodies in lung cancer. Br J Cancer 43: 276–285PubMedCrossRefGoogle Scholar
  25. Hadziev S, Kavaklieva-Dimitrova J (1969) Application of BCG in cancer in man. Folia Med (Plovdiv) 11: 8–13Google Scholar
  26. Hadziev S, Kavaklieva-Dimitrova J, Mandulova P, Madzarova S, Spassova M (1980) Survival of lung cancer patients treated with BCG and/or a soluble BCG fraction (F 70) after surgery, radiotherapy and chemotherapy. Neoplasma 27: 83–94PubMedGoogle Scholar
  27. Halpern BN, Biozzi G, Stiffel C, Mouton D (1959) Effect of stimulation of the reticuloendothelial system by injection of BCG on the development of atypical epithelioma 7–8 of Guèrin in the rat. C R Soc Biol (Paris) 153: 919–923Google Scholar
  28. Halpern BN, Prévot A-R, Biozzi G et al. (1964) Stimulation of the phagocyte activity of the reticuloendothelial system provoked by Corynebacterium parvum. J Reticuloendothel Soc 1: 77–96Google Scholar
  29. Han T, Takita H (1976) Inhibition of mixed lymphocyte reaction by thoracic duct lymph: removal of inhibitory effect by thoracic duct drainage in lung cancer. J Surg Oncol 8: 237–243PubMedCrossRefGoogle Scholar
  30. Hansen M, Hammer M, Hummer L (1980) ACTH, ADH and calcitonin concentrations as markers of response and relapse in small-cell carcinoma of the lung. Cancer 46: 2062–2067PubMedCrossRefGoogle Scholar
  31. Herberman RB, McIntire KR, Braatz J et al. (1978) Antigenic markers associated with lung cancer. In: Krebs BP, Lalanne CM, Schneider M (eds) Clinical application of carcinoembryonic antigen assay. Excerpta Medica International Congress Series, vol 439: 165–174Google Scholar
  32. Herberman RB, Timonen T, Ortaldo JR, Bonnard GD, Gorelik E (1980) Natural cell-mediated toxicity. In: Fougereau M, Dausset J (eds) Progress in Immunology, vol 4. Academic Press, London New York, pp 691–709Google Scholar
  33. Hollinshead AC, Stewart THM (1981) Specific and non-specific immunotherapy as an adjunct to curative surgery for cancer of the lung. Yale J Biol Med 54: 367–379PubMedGoogle Scholar
  34. Holmes EC (1981) The immunotherapy of lung cancer. In: Livingston RB (ed) Lung cancer, vol 1. Mattinus Nijhoff, The Hague, pp 51–62Google Scholar
  35. Holmes EC (1982) Surgical adjuvant intrapleural BCG. In: Abstracts of the 3rd World Conference on Lung Cancer, IASLC, Tokyo, p 10Google Scholar
  36. Holmes EC, Golub SH (1976) Immunologic defects in lung cancer patients. J. Thorac Cardiovasc Surg 71: 161–168PubMedGoogle Scholar
  37. loachim HL, Dorsett BH, Paluch E (1976) The immune response at the tumor site in lung carcinoma. Cancer 38: 2296–2309CrossRefGoogle Scholar
  38. Israel L (1974) Non-specific immunostimulation in bronchogenic cancer. Scand J Resp Dis [Suppl] 89: 95–105Google Scholar
  39. Jansen HM, Esselink MT, Orie NGM, The TH (1979) Cell-mediated immune response in patients with bronchial carcinoma. Neth J Med 22: 1–9Google Scholar
  40. Jonsdottir I, Dillner-Centerlind M-L, Perlmann H, Perlmann P (1979) Antibody dependent cellular cytotoxicity and mitogen responsiveness of human peripheral blood lymphocytes differing in avidity for sheep erythrocytes. Scand J Immunol 10: 525–533PubMedCrossRefGoogle Scholar
  41. Karrer K (1982) Adjuvant immunotherapy for non-small cell bronchial carcinoma. In: Abstracts of the 3rd World Conference on Lung Cancer, IASLC, Tokyo, p 8Google Scholar
  42. Kay AB McVie JG (1977) Monocyte chemotaxis in bronchial carcinoma and cigarette smokers. Br J Cancer 36: 461–466PubMedCrossRefGoogle Scholar
  43. Kennel SJ (1979) Characterisation of a tumour cell surface protein with heterologous antisera to a spontaneous BALC/c lung carcinoma. Cancer Res 39: 2934–2939PubMedGoogle Scholar
  44. Kimura H, Yamaguchi Y, Kadoyama C et al. (1982) Induction and clinical application of specific immune lymphocytes against autologous lung cancer cells. In: Abstracts of 3rd World Conference on Lung Cancer, IASLC, Tokyo, p 142Google Scholar
  45. Kjeldsberg CR, Pay GD (1978) A qualitative and quantitative study of monocytes in patients with malignant solid tumours. Cancer 41: 2236–2241.PubMedCrossRefGoogle Scholar
  46. Lipson SD, Chretien PB, Makuch R, Kenady DE, Cohen M (1979) Thymosin immunotherapy in patients with small cell carcinoma of the lung. Cancer 43: 863–870PubMedCrossRefGoogle Scholar
  47. Livingston RB (1981) Preface. In: Livingston RB (ed) Lung cancer, vol 1. Martinus Nijhoff, The Hague, p11Google Scholar
  48. Loeffler F (1901) A new method of treating carcinomas. Dtsch Med Wochenschr 27: 725–726CrossRefGoogle Scholar
  49. Lowe J, Iles PB, Shore DF, Langman MJS, Baldwin RW (1980) Intrapleural BCG in operable lung cancer. Lancet 1: 11–14PubMedCrossRefGoogle Scholar
  50. Lowe J, Segal-Eiras A, Iles PB, Baldwin RW (1981) Circulating immune complexes in patients with lung cancer. Thorax 36: 56–59PubMedCrossRefGoogle Scholar
  51. Mantovani A, Giavazzi R, Polentarutti N, Spreafico F, Garattini S (1980) Divergent effects of macrophage toxins on growth of primary tumours and lung metastases in mice. Int J Cancer 25: 617–620PubMedCrossRefGoogle Scholar
  52. Marabella PC, Takita H (1975) Skin test with tumour extract in bronchogenic carcinoma: a preliminary study. J Surg Oncol 7: 299–301PubMedCrossRefGoogle Scholar
  53. Mayer C, Kausel H, Lininger L, McKneally M (1982) Intrapleural BCG immunotherapy of lung cancer patients. In: Mathé G, Bonnadonna G, Salmon S (eds) Adjuvant therapies of cancer. Springer, Berlin Heidelberg New York, pp 227–231Google Scholar
  54. McKneally MF, Mayer C, Kausel HW (1976) Regional immunotherapy of lung cancer with intrapleural BCG. Lancet 1: 377–381PubMedCrossRefGoogle Scholar
  55. Millar JW, Hunter AM, Home NW (1980a) Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions. Thorax 35: 856–858PubMedCrossRefGoogle Scholar
  56. Millar JW, Hunter AM, Wightman AJA, Home NW (1980b) Intralesional injection of BCG using the fibreoptic bronchoscope in the treatment of bronchogenic carcinoma. Eur J Respir Dis 61: 162–166PubMedGoogle Scholar
  57. Millar JW, Roscoe P, Pearce S, Ludgate S, Home NW (1982) The five year results of a controlled study of BCG immunotherapy after surgical resection for bronchogenic carcinoma. Thorax 37: 57–60PubMedCrossRefGoogle Scholar
  58. Mitchison NA, Kinlen LJ (1980) Present concepts in immune surveillance. In: Fougereau M, Dausset J (eds) Progress in Immunology, vol 4. Academic Press, London New York, pp 641–650Google Scholar
  59. Miyazawa N, Suemasu K, Ogata T, Yoneyama T, Naruke T, Tsuchiya A (1979) BCG immunotherapy as an adjuvant to surgery in lung cancer: a randomised prospective clinical trial. Jpn J Clin Oncol 9: 19–26Google Scholar
  60. Morena L, Mingari MC, Moretta A, Haynes BG, Fauci AS (1980) T cell Fc receptor as markers of functional human lymphocyte subsets. In: Fougereau M, Dausset J (eds) Progress in Immunology, vol 4. Academic Press London New York pp 223–238Google Scholar
  61. Newman CE, Ford CHJ, Davies DAL, O’Neill GJ (1977) Antibody-drug synergism: an assessment of specific passive immunotherapy in bronchial carcinoma. Lancet II: 163–166Google Scholar
  62. Niitsuma M, Golub SH, Edelstein R, Holmes EC (1981) Lymphoid cells infiltrating human pulmonary tumours: effect of intralesional BCG injection. J Natl Cancer Inst 67: 997–1003PubMedGoogle Scholar
  63. Oshima S, Izumi T, Kado M, Sato A, Honda K (1980) Immunotherapy with schizophyllan of lung cancer. In: Hansen HH, Dombernowsky P (eds) Abstracts of Second World Conference on Lung Cancer, p 193Google Scholar
  64. Ota DM, Copeland EM, Corriere JN, Dudrick SJ (1979) The effects of nutrition and treatment of cancer on host immunocompetence. Surg Gynecol Obstet 148: 104–111PubMedGoogle Scholar
  65. Parkinson DR, Cano PO, Jerry LM et al. (1977) Complications of cancer immunotherapy with levamisole. Lancet 1: 1129–1132PubMedCrossRefGoogle Scholar
  66. Penn I (1978) Tumours arising in organ transplant recipients. Adv Cancer Res 28: 31–36PubMedCrossRefGoogle Scholar
  67. Perlin E, Oldham RK, Weese JL et al. (1980) Carcinoma of the lung: immunotherapy with intradermal BCG and allogeneic tumour cells. Int J Radiat Oncol Biol Phys 6: 1003–1039CrossRefGoogle Scholar
  68. Pines A (1976) A 5 year controlled study of BCG and radiotherapy for inoperable lung cancer. Lancet I: 380–381Google Scholar
  69. Pouillart P, Palangie T, Huguenin P et al. (1979) Attempt at immunotherapy with living BCG in patients with bronchus carcinoma. Rec Res Cancer Res 68: 260–267CrossRefGoogle Scholar
  70. Reddy MN, Rochman H, Hunter RL, Fang VS, De Meester T (1979) Carcinoembryonic antigen, k-casein and ß-human chorionic gonadotropin in the staging of lung cancer. In: Lehmann F-G (ed) Carcino-embryonic proteins, vol II. Elsevier/North Holland Biochemical Press, Amsterdam Oxford New York, pp 173–176Google Scholar
  71. Reid JW, Cannon GB, Perlin E, Blom J, Connor R, Herberman RB (1982) Immunologically defined prognostic subgroups as predictors of response to BCG immunotherapy. In: Mathé G, Bonnadonna G, Salmon S (eds) Adjuvant therapies of cancer. Springer Berlin Heidelberg New York, pp 219–226Google Scholar
  72. Ritts RE, Jacobsen DA, Caron J, Weyl KG et al. (1977). Is the lung cancer patient immunologically competent? In: Perspectives in lung cancer. Frederick E Jones Memorial Symposium in Thoracic Surgery, Columbus, Ohio. Karger, Basel, pp 47–56Google Scholar
  73. Rossen RD, Reisberg MA, Hersh EM, Gutterman JU (1977) The CIq binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. J Natl Cancer Inst 58: 1205–1215PubMedGoogle Scholar
  74. Sanner T, Kotlar HK, Eker P (1980) Immune responses in lung cancer patients measured by a modified leukocyte adherence inhibition test using serum. Cancer Lett 8: 283–290PubMedCrossRefGoogle Scholar
  75. Saumon G, Dermenghem F, Saint-Paul M, Sors C, Decroix G (1968) Study of the culture of lymphocytes in the course of broncho-pulmonary cancer. Presse Medic 76: 1657–1660Google Scholar
  76. Sengar DPS, McLeish WA, Stewart THM, Harris JE (1977) HLA antigens in bronchogenic carcinoma. Oncology 34: 143–145PubMedCrossRefGoogle Scholar
  77. Serrou B, Cupissol D, Rosenfeld C (1982) Immune imbalance and immune modulation in solid tumour patients: new insights. In Mathé G, Bonadonna G, Salmon S (eds) Adjuvant therapies of cancer. Springer, Berlin Heidelberg New York, pp 9–16CrossRefGoogle Scholar
  78. Sjögren HO, Hellström I, Bansal SC, Hellström KE (1971) Suggestive evidence that the `blocking antibodies’ of tumour bearing individuals may be antigen-antibody complexes. Proc Natl Acad Sci USA 68: 1372–1375PubMedCrossRefGoogle Scholar
  79. Soorae AS, Stevenson HM (1979) Survival with residual tumour on bronchial margin after resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg 78: 175–180PubMedGoogle Scholar
  80. Stack BHR (1982) Immunological investigations and immunotherapy in lung cancer. MD Thesis, University of Edinburgh, pp 105–111Google Scholar
  81. Stack BHR, McSwan N, Stirling JM et al. (1979) Cell-mediated immunity in operable bronchial carcinoma: the effect of injecting irradiated autologous tumour cells and BCG. Thorax 34: 68–73PubMedCrossRefGoogle Scholar
  82. Stack BHR, McSwan N, Stirling JM et al. (1982) Autologus X-irradiated tumour cells and percutaneous BCG in operable lung cancer. Thorax 37: 588–593PubMedCrossRefGoogle Scholar
  83. Stevens DP, Mackay IR, Busselton Population Studies Group (1973) Increased carcinoembryonic antigen in heavy cigarette smokers. Lancet II: 1238–1239Google Scholar
  84. Stewart THM (1969) The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumours. Cancer 23: 1368–1387PubMedCrossRefGoogle Scholar
  85. Stewart THM, Hollinshead AC, Harris JE, Raman S (1982) Specific active immunotherapy in lung cancer: the induction of long-lasting cellular responses to tumour-associated antigens. In: Mathe G, Bonadonna G, Salmon S (eds) Adjuvant therapy of cancer. Springer, Berlin Heidelberg New York, pp 232–239CrossRefGoogle Scholar
  86. Svanberg L, Widell A, Cronberg S (1980) Clinical and immunological investigation of the effect of bestatin. In: Hansen HH, Domebernowsky P (eds) Abstracts of Second World Conference on Lung Cancer, p 196Google Scholar
  87. Syrjanen KJ (1979) Bronchial carcinoma and its regional lymph nodes in relation to immunological functions. Z Immunitaets Forsch 155: 212–222Google Scholar
  88. Takita H, Minowada J, Han T, Takada M, Lane WW (1976) Adjuvant immunotherapy in bronchogenic carcinoma. Ann NY Acad Sci 277: 345–354PubMedCrossRefGoogle Scholar
  89. Takita H, Hollinshead AC, Edgerton F et al. (1981) Adjuvant immunotherapy of squamous cell lung carcinoma. Proc Am Assoc Cancer Res 22: 199Google Scholar
  90. Uchida A, Micksche M (1982) Intrapleural administration of OK-432 in cancer patients: activation of natural killer (NK) cells and reduction of NK suppressor cells. In: Abstracts of the 3rd World Conference on Lung Cancer, IASLC, Tokyo, p 145Google Scholar
  91. Vincent RG, Chu TM, Lane WW (1979) The value of carcinoembryonic antigen in patients with carcinoma of the lung. Cancer 44: 685–691PubMedCrossRefGoogle Scholar
  92. Von Leyden E, Blumenthal F (1902) Preliminary information about results of cancer research from the first medical clinic. Dtsch Med Wochenschr 28: 637–638CrossRefGoogle Scholar
  93. Vose BM, Moore M (1979) Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours. Int J Cancer 24: 579–585PubMedCrossRefGoogle Scholar
  94. Watanabe Y, Iwa T, Yamamoto K (1980) Clinical value of immunotherapy by streptococcal preparation OK-432 as an adjuvant for resected lung cancer. In: Hansen HH, Dombernowsky P (eds) Abstracts of Second World Conference on Lung Cancer, p 198Google Scholar
  95. Whitcomb ME, Parker RL (1977) Abnormal lymphocyte protein synthesis in bronchogenic carcinoma. Cancer 40: 3014–3018PubMedCrossRefGoogle Scholar
  96. Wilmott N, Pimm MV, Baldwin RW (1979) Quantitative comparison of BCG strains and preparations in immunotherapy of rat sarcoma. J Natl Cancer Inst 63: 787–795Google Scholar
  97. Wolf A, Micksche M, Bauer H (1981) An improved antigenic marker of human lung carcinomas and its use in radioimmunoassays. Br J Cancer 43: 267–275PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • Bryan H. R. Stack

There are no affiliations available

Personalised recommendations